Summary of the Conference Call for Dongcheng Pharmaceutical Company Overview - **Company**: Dongcheng Pharmaceutical - **Date**: March 29, 2026 Key Industry Insights - **FDG Product Growth**: Expected to grow nearly 20% in 2025, driven by regional management improvements, new capacity contributions, and healthcare pricing policies encouraging hospitals to purchase rather than self-produce [2][3] - **Nuclear Medicine Strategy**: The "one pile, two devices" strategy aims to establish a unique position in the market by developing both reactor and accelerator technologies, with the Ac-225 accelerator project expected to be completed by the end of 2026 [2][4] - **Heparin Raw Material Pricing**: Prices have dropped to $30/unit, with continued downward pressure expected in 2026, although demand is recovering, maintaining an overall gross margin above 40% [2][9] Core Business Developments - **CMO Business Expansion**: The Andyco platform has signed 11 agreements, with 5-6 centers expected to start production in the second half of 2026 [2][6] - **Innovative Pipeline**: - LNC1,016 and RNC1,005 are expected to enter Phase III trials in 2026 [5][6] - Lu-177 RNC1,011 is showing promising Phase II data, with plans to enter Phase III in Q1 2027 [5][7] - **IPO Progress**: The IPO application for Lanacheng has been submitted, which, if successful, will significantly reduce financial expenses for the company [2][10] Regulatory and Market Dynamics - **New Regulations Impact**: The implementation of new regulations in May 2026 may limit hospitals' ability to self-produce FDG, potentially increasing market opportunities for compliant commercial suppliers like Dongcheng [2][18] - **Market Demand Recovery**: As the economy recovers, both insurance-covered and out-of-pocket markets are expected to see increased demand for FDG products [3][4] Financial Outlook - **2026 Financial Guidance**: The company anticipates stable sales, management, and financial expenses compared to 2025, with potential reductions in financial expenses contingent on the IPO progress of Lanacheng [10][12] - **Asset Quality**: The company reports stable asset quality with minimal expected impairment pressure moving forward, despite previous challenges [19][20] Strategic Vision - **Long-term Strategy**: The company aims to maintain strategic focus and steady growth, leveraging traditional business cash flow to support innovation in nuclear medicine while optimizing costs and enhancing core competencies [21] Additional Insights - **Collaborations**: The company is exploring partnerships with multinational corporations (MNCs) for service provision and product development, focusing on enhancing its competitive edge in the nuclear medicine sector [13][15] - **Clinical Trial Dynamics**: The clinical trial timelines for nuclear medicines vary, with diagnostic drugs yielding quicker data compared to therapeutic drugs, which require longer follow-up periods [14] This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic initiatives, market dynamics, and financial outlook.

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The animal health raw material drug prices are expected to experience a cyclical rebound in 2026 due to a recovery in industry demand and stabilization of antibiotic supply chain prices [1] - The heparin raw material drug industry is currently at a cyclical low, with prices declining sharply in 2023, but expected to stabilize by 2025 [2][56] - The vitamin industry is entering a price increase cycle influenced by geopolitical tensions and rising oil prices, leading to significant price increases for vitamin A and E [3][58] Summary by Sections Raw Material Prices and Trends - The PPI index for China's chemical raw materials has been on a downward trend, while upstream raw material prices are showing an upward trend, which may accelerate the supply clearance in the raw material drug industry [11][18] - Antibiotic prices, including 6-APA and penicillin industrial salt, are showing signs of recovery after hitting bottom [25][29] - The average price of florfenicol has dropped from 400-700 RMB/kg to 150-200 RMB/kg, indicating a significant decline due to oversupply and weak downstream demand [46][49] Investment Recommendations - The report suggests focusing on companies that have undergone thorough supply clearance and have expectations for price increases, recommending stocks such as Guobang Pharmaceutical, Puluo Pharmaceutical, and Aorite [4][72] - Beneficiary stocks include Meinuo Pharmaceutical, Chuaning Biological, and Zhejiang Pharmaceutical, among others [4][72] Price Trends in Specific Segments - Heparin API prices are expected to stabilize in 2025 after a period of decline due to oversupply [56][57] - Iodine raw material prices have seen a recovery due to strong demand from other industries, following a period of significant price increases [2][56] - The vitamin A and E prices are experiencing rapid increases due to geopolitical tensions affecting oil prices and supply chain disruptions [3][58]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform" [1] Core Insights - The vitamin raw material market is entering a price increase phase, with significant potential for further price rises. Key products such as VE, niacin (VB3), and folic acid (VB9) have already started to increase in price, with VA and calcium pantothenate expected to follow suit [4][6][43] - Antibiotic raw materials, particularly penicillin, have seen price increases due to India's MIP policy, with 6-APA showing the most significant rise [6][25] - The overall market for raw materials is experiencing structural recovery, with various segments showing different price trends [15][21] Summary by Sections 1. Raw Material Market Recovery - Vitamins are starting to rise from historical lows, with VE currently priced at 78 CNY/kg, showing a 35.65% increase over the past month and a 40.54% increase over three months [15][21] - Antibiotic prices, particularly for 6-APA, have increased by 17.11% in the last month, influenced by India's import price policies [15][25] - Hormones and analgesics are maintaining stable prices, while cardiovascular raw materials show no significant price fluctuations [16][33] 2. Industry Outlook and Investment Recommendations - The pharmaceutical sector has underperformed, with a 0.22% decline in the A-share pharmaceutical index, lagging behind the CSI 300 index by 0.41 percentage points [5][42] - Investment opportunities are identified in companies like Yifan Pharmaceutical, Zhejiang Medicine, and Nengte Technology, which are positioned to benefit from rising vitamin prices [6][46] - The innovative drug sector is expected to see continued growth, with companies like Innovent Biologics and 3SBio showing promise in the market [8][45] 3. Medical Devices - The medical device industry is anticipated to improve significantly in 2026, with the negative impacts of centralized procurement diminishing [49][50] - The surgical robot sector is highlighted as a key area for growth, with upcoming policy changes expected to standardize pricing and enhance market penetration [49][50]

Group 1 - On January 30, Changshan Pharmaceutical's stock rose by 5.28%, with a trading volume of 1.538 billion yuan [1] - The company had a financing buy amount of 104 million yuan and a financing repayment of 111 million yuan on the same day, resulting in a net financing buy of -7.81 million yuan [1] - As of January 30, the total margin balance for Changshan Pharmaceutical was 2.608 billion yuan, accounting for 5.12% of its circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of January 20, the number of shareholders for Changshan Pharmaceutical was 41,400, an increase of 2.88% from the previous period [2] - The average circulating shares per person decreased by 2.79% to 22,148 shares [2] - For the period from January to September 2025, the company reported an operating income of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to the parent company of -44.82 million yuan, a decrease of 714.77% year-on-year [2] Group 3 - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the sixth largest circulating shareholder, holding 3.8944 million shares, a decrease of 6.6577 million shares from the previous period [3]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin API prices are stabilizing, while iodine raw material prices are expected to rise in 2025 due to previous supply constraints [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, among others [8] - Weekly recommended stocks include Kanglong Chemical, WuXi AppTec, and Aopumai [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin raw material prices have stabilized after a period of decline, while iodine raw material prices are expected to rise again in 2025 due to increased demand [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, while weekly recommendations feature companies like Kanglong Chemical and Yao Ming He Lian [8]

Group 1 - The U.S. Trade Representative (USTR) announced an extension of tariff exemptions on 178 items until November 10, 2026, reflecting the complex dynamics of U.S.-China trade relations [1][2] - The extension is seen as a necessary compromise, highlighting the rigid demand of the U.S. industry for Chinese supply chains, particularly in critical sectors like electronics and medical supplies [3][5] - The exemptions include essential products such as heparin, which accounts for nearly 80% of global supply, indicating the U.S. healthcare system's reliance on Chinese imports [5] Group 2 - The extension of tariff exemptions is a strategic move to provide stability for U.S. domestic industries, especially in healthcare and renewable energy, amidst rising costs due to tariffs [7] - The decision aligns with previous U.S.-China economic discussions, suggesting a shift towards pragmatic dialogue and cooperation after years of trade tensions [7] - The extended exemption period offers an opportunity for Chinese companies to strengthen their market position and enhance technological advancements while testing the resilience of U.S.-China relations [7][9] Group 3 - The situation illustrates the broader economic reality that political maneuvers cannot easily disrupt the interdependent nature of global supply chains [9] - The ongoing trade friction emphasizes the importance of economic fundamentals over political rhetoric, suggesting that a nation's resilience and adaptability will ultimately define its global standing [9]

Core Insights - The article discusses the phenomenon of continuous net buying by institutional investors in certain stocks, highlighting the disparity between retail and institutional investor behavior [1][3][7] - It emphasizes the importance of understanding the underlying data behind stock movements, particularly the "institutional inventory" data, to differentiate between sustainable growth and temporary spikes [5][7][8] Group 1: Market Behavior - The current market is characterized as a "liquidity bull market," where retail investors often react too late to market movements, leading to missed opportunities and losses [3][7] - The article draws a parallel to the quote from Qian Zhongshu's "Fortress Besieged," illustrating the conflicting desires of investors inside and outside the market [3] Group 2: Institutional vs. Retail Investors - Retail investors tend to enter the market after institutional investors have already made their moves, resulting in a detrimental time lag that can lead to significant losses [3][7] - The analysis of two contrasting stocks reveals that while one stock had a strong rebound, it lacked institutional support, indicating a potential trap for retail investors [5][7] Group 3: Stock Analysis - The article highlights 84 stocks that have seen continuous net buying from major funds, questioning whether this buying behavior is part of a strategic long-term investment or a short-term tactical move [7] - Historical data shows that stocks with a sustained upward trend in "institutional inventory" are more likely to experience long-term growth, while those with erratic inventory patterns may only see temporary gains [7] Group 4: Earnings Reports and Market Expectations - As the third-quarter earnings reports approach, the focus will shift to performance expectations, with "expectation gaps" being more critical than the earnings figures themselves [7] - The article suggests that monitoring changes in "institutional inventory" around earnings announcements can provide insights into whether institutions are selling on good news or buying into the stock [7][8]

Core Viewpoint - Changshan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 148.82%, despite recent fluctuations in trading volume and net capital flow [1][2]. Group 1: Stock Performance - As of October 20, Changshan Pharmaceutical's stock price reached 49.74 CNY per share, with a market capitalization of 457.14 billion CNY [1]. - The stock has experienced a 2.05% increase during the trading session on October 20, with a trading volume of 3.56 billion CNY and a turnover rate of 0.80% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on June 19, where it recorded a net buy of -178 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 4.92 billion CNY, a year-on-year decrease of 13.42%, while the net profit attributable to shareholders was -29.09 million CNY, an increase of 37.98% year-on-year [2]. - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1]. Group 3: Shareholder Information - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per shareholder, an increase of 2.08% [2]. - The company has distributed a total of 1.81 billion CNY in dividends since its A-share listing, with 4.60 million CNY distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 10.55 million shares, an increase of 8.04 million shares from the previous period [3].

Core Viewpoint - Changshan Pharmaceutical experienced a 5.07% increase in stock price, reaching 50.99 CNY per share, with a trading volume of 976 million CNY and a market capitalization of 46.863 billion CNY as of October 15 [1] Company Overview - Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is located in the Hebei Free Trade Zone and was established on September 28, 2000, with its listing date on August 19, 2011 [1] - The company's main business involves the research, production, and sales of heparin series products, with revenue composition as follows: 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Fund Holdings - According to data, one fund under Bosera Asset Management holds a significant position in Changshan Pharmaceutical. The Bosera National Index 2000 ETF (159505) held 1,400 shares in the second quarter, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF (159505) was established on November 23, 2023, with a latest scale of 11.7815 million CNY. Year-to-date returns are 37.61%, ranking 997 out of 4,220 in its category, while the one-year return is 49.48%, ranking 579 out of 3,857 [2] Fund Manager Information - The fund manager of Bosera National Index 2000 ETF (159505) is Tang Yibing, who has been in the position for 3 years and 87 days. The total asset size of the fund is 9.874 billion CNY, with the best return during his tenure being 72.49% and the worst being -41.93% [3]